Pain Therapeutics Reports Q2 2014 Financial Results

Pain Therapeutics Reports Q2 2014 Financial Results

Conference Call Today at 4:30 p.m. Eastern Time

AUSTIN, Texas, Aug. 5, 2014 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc.
(Nasdaq:PTIE) today reported financial results for Q2 2014. Net loss in Q2
2014 was $3.2 million, or $0.07 per share, compared to a net loss in Q2 2013
of $0.3 million, or $0.01 per share. Net cash used in Q2 2014 was $2.3
million. At June 30, 2014, cash and investments were $44.8 million. As
previously disclosed, the Company believes net cash usage for 2014 may be
approximately $12 million.

"In early 2014, we informed shareholders we would widen our pipeline of drug
assets, while maintaining tight fiscal discipline," said Remi Barbier,
Chairman, President & CEO."At this mid-year mark, I'm pleased to report our
strategy is moving along very well.We continue to believe Pfizer will file an
NDA for REMOXY in 2015, we plan to initiate a clinical trial with a new
abuse-resistant pain drug (hydromorphone) in the next quarter and we plan to
disclose a novel pain product second half of 2014."

Financial Highlights for Q2 2014

  oAt June 30, 2014, cash and investments were $44.8 million, compared to
    $49.8 million at December 31, 2013.We have no debt.
  oNet cash used in Q2 2014 was $2.3 million.
  oResearch and development expenses increased to $1.9 million in Q2 2014
    from $1.1 million in Q2 2013, primarily due to increased investment in
    early stage drug assets.Research and development expenses included
    non-cash stock-related compensation costs of $0.4 million in Q2 2014 and
    $0.3 million in Q2 2013.
  oGeneral and administrative expenses increased to $1.3 million in Q2 2014
    from $1.1 million in Q2 2013.General and administrative expenses included
    non-cash stock-related compensation costs of $0.5 million in both Q2 2014
    and Q2 2013.
  oPTIE was added to the Russell 2000 Index and Russell 3000 Index on June
    27, 2014.

About REMOXY^®

Our lead drug candidate, REMOXY (oxycodone) Extended-Release Capsules CII, is
an oral formulation of oxycodone for the management of moderate-to-severe pain
when a continuous, around-the-clock opioid analgesic is needed for an extended
period of time.We designed REMOXY to discourage common methods of tampering
and misuse.Pfizer, Inc. (NYSE:PFE) is our exclusive, worldwide commercial
partner for REMOXY, except as to Australia and New Zealand.

REMOXY Deal Economics

  *To date, we have received total cash payments of $185 million in program
    fees and milestone payments under our strategic alliance with Pfizer.
  *We are eligible to receive from Pfizer a $15.0 million payment upon FDA
    approval of REMOXY.
  *After the commercial launch of REMOXY by Pfizer, we will receive a royalty
    of 20% of net sales in the United States, except as to the first $1.0
    billion in cumulative net sales, which royalty is set at 15%.Outside the
    United States, the royalty rate is 10%.
  *We will also receive from Pfizer a supplemental payment of 6.0% to 11.5%
    of net sales, depending on the range of total dollar sales in each year,
    covered by the strategic alliance. This supplemental payment is tied to
    the full amount of our financial obligations to Durect Corporation, our
    exclusive supplier of certain excipients in REMOXY.
  *All development and commercialization expenses around REMOXY are
    reimbursed or paid for by Pfizer.
  *We retain commercial rights to REMOXY in Australia/New Zealand.We have
    not yet announced a market entry strategy for these territories.
  *As previously announced, in October 2013 Pfizer returned to us all rights
    with respect to abuse-resistant formulations of three opioid drugs:
    hydrocodone, hydromorphone and oxymorphone.We are free to develop and
    commercialize these assets on our own or with a licensee of our choice,
    and may do so without notice or approval from Pfizer.We have not yet
    announced a market entry strategy for these drug assets.

Conference Call

Pain Therapeutics will host a conference call today at 4:30 p.m. Eastern time
to discuss Q2 2014 financial results and respond to questions from investors.

Participants may access the call by dialing 1-877-407-4018 in the U.S. or
1-201-689-8471 outside the U.S. The call will be webcast live on the Company's
website at www.paintrials.com. A replay of the call will be available for
approximately 7 days after the live event.To access the replay, please dial
1-877-870-5176 in the U.S. or 1-858-384-5517 outside the U.S. The replay
access code is 13587588.

About Pain Therapeutics, Inc.

Pain Therapeutics, Inc. is a biopharmaceutical company that develops novel
drugs. The FDA has not approved any of our drug candidates for commercial
sale. For more information, please visit www.paintrials.com.

Note Regarding Forward-Looking Statements: This press release contains
forward-looking statements for purposes of the Private Securities Litigation
Reform Act of 1995 (the "Act").Pain Therapeutics disclaims any intent or
obligation to update these forward-looking statements, and claims the
protection of the Safe Harbor for forward-looking statements contained in the
Act.Examples of such statements include, but are not limited to, any
statements relating to the company's projected cash use for 2014; potential
future milestone payments; reimbursement of development expenses for REMOXY;
royalty and supplemental payments based on net sales of REMOXY; and the
potential benefits of REMOXY.Such statements are based on management's
current expectations, but actual results may differ materially due to various
factors. Such statements involve risks and uncertainties, including, but not
limited to, those risks and uncertainties relating to difficulties or delays
in obtaining regulatory approval of REMOXY and in development and testing of
our other drug candidates; unexpected adverse side effects or inadequate
therapeutic efficacy of our drug candidates; difficulties or delays in
commercialization efforts with respect to REMOXY, if approved for marketing,
or failure of REMOXY to gain market acceptance; the uncertainty of patent
protection for our intellectual property or trade secrets; unanticipated
additional research and development, litigation and other costs; the receipt
of funds from Pfizer; potential diversion of resources from the pursuit of
development and commercialization of REMOXY; and the potential for
abuse-resistant pain medications or other competing products or therapies to
be developed by competitors and potential competitors or others.For further
information regarding these and other risks related to the Company's business,
investors should consult the Company's filings with the Securities and
Exchange Commission.

                         – Financial Tables Follow –


PAIN THERAPEUTICS, INC.
CONDENSED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(Unaudited)
                                                             
                        Three Months Ended June   Six Months Ended June 30,
                         30,
                        2014          2013        2014         2013
Revenue                                                    
Program fee revenue    $ —          $1,959     $—          $3,917
Total revenue          —            1,959      —           3,917
Operating expenses                                         
Research and            1,935        1,139      4,081       2,322
development
General and             1,322        1,139      2,639       2,357
administrative
Total operating         3,257        2,278      6,720       4,679
expenses
Operating loss         (3,257)      (319)      (6,720)     (762)
Interest income        11           18         25          53
Net loss               $(3,246)     $(301)     $(6,695)    $(709)
Net loss per share,      $(0.07)      $(0.01)    $(0.15)     $(0.02)
basic and diluted
Weighted-average shares
used in computing        45,247       44,999     45,187      44,966
netloss per share,
basic and diluted
                                                             
CONDENSED BALANCE SHEETS
(in thousands)
                                                June 30,     December 31,
                                                   2014         2013^(1)
                                                (Unaudited)  
Assets                                                     
Current assets                                             
Cash, cash equivalents
and marketable                                   $44,825     $49,838
securities
Other current assets                           482         265
Total current assets                           45,307      50,103
Property and equipment                         72          —
Other assets                                   12          —
Total assets                                   $45,391     $50,103
Liabilities and                                             
stockholders' equity
Current liabilities                                        
Accounts payable and
accrued development                              $692        $1,086
expenses
Other accrued                                   1,047       715
liabilities
Total current                                   1,739       1,801
liabilities
Non-current                                     —           —
liabilities
Total liabilities                              1,739       1,801
Stockholders' equity                                       
Common Stock and
additional                                       154,454     152,408
paid-in-capital
Accumulated other                               —           1
comprehensive income
Accumulated deficit                            (110,802)   (104,107)
Total stockholders'                             43,652      48,302
equity
Total liabilities and                           $45,391     $50,103
stockholders' equity
                                                            
^(1) Derived from the Company's annual financial statements as of December 31,
2013, included in the Company's Annual Report on Form 10-K filed with the
Securities and Exchange Commission.

CONTACT: Peter S. Roddy
         Vice President and Chief Financial Officer
         Pain Therapeutics, Inc.
         proddy@paintrials.com
         (512) 501-2450
        
         Barbara Ryan
         FTI Consulting
         Barbara.ryan@fticonsulting.com
         (212) 850-5679
 
Press spacebar to pause and continue. Press esc to stop.